Sign In
Buy OCGN
$1.21
-0.0100 (-0.82%)
At Close: Jun 12, 2026
Ocugen Stock Is Surging Today: What's Driving The Action?
12:07pm, Friday, 16'th Jan 2026
Ocugen Inc (NASDAQ: OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.
Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript
02:16pm, Thursday, 15'th Jan 2026
Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript
Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage
01:15pm, Thursday, 15'th Jan 2026
Ocugen, Inc. (NASDAQ: OCGN) on Thursday shared preliminary data from its phase 2 clinical trial for OCU410, a gene therapy targeting geographic atrophy.
MALVERN, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positiv
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
07:00am, Tuesday, 13'th Jan 2026
MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today annou
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
06:30am, Monday, 12'th Jan 2026
MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pub
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
07:02am, Friday, 09'th Jan 2026
MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr
Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments
12:20am, Tuesday, 06'th Jan 2026
Ocugen remains a "Buy", driven by pivotal phase 2/3 GARDian3 trial progress for OCU410ST in Stargardt Disease. FDA and EMA regulatory alignment enables a single U.S. trial to support both BLA and MAA
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
10:55am, Monday, 29'th Dec 2025
Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
Ocugen Target of Unusually High Options Trading (NASDAQ:OCGN)
02:07am, Saturday, 27'th Dec 2025
Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) saw some unusual options trading activity on Friday. Stock investors bought 6,390 call options on the stock. This represents an increase of approximately
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
10:26am, Tuesday, 16'th Dec 2025
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements wit
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
09:20am, Wednesday, 10'th Dec 2025
MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr
Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference
07:02am, Thursday, 20'th Nov 2025
MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr
Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript
04:21pm, Wednesday, 05'th Nov 2025
Ocugen, Inc. ( OCGN ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Tiffany Hamilton - AVP & Head of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Ra
Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates
11:56am, Wednesday, 05'th Nov 2025
Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.05 per share a year ago.
